Skip to main content
ARGENT BIOPHARMA LIMITED logo

ARGENT BIOPHARMA LIMITED — Investor Relations & Filings

Ticker · RGT ISIN · AU0000326647 LEI · 213800HRE3FQJ6RK4H10 ASX Manufacturing
Open in API
Filings indexed 1,296 across all filing types
Latest filing 2026-05-24 Regulatory Filings
Country AU Australia
Listing ASX RGT

About ARGENT BIOPHARMA LIMITED

https://argentbiopharma.com

Argent Biopharma Limited is a biopharmaceutical company focused on the development and commercialization of innovative, plant-inspired, and synthetic medicines. The company specializes in addressing unmet medical needs within the fields of neurology and immunology. Its research and development pipeline features treatments for refractory epilepsy, dementia, and systemic inflammatory conditions. Key products include CannEpil, a phytocannabinoid-derived formulation for epilepsy, and CogniCann, aimed at improving the quality of life for patients with dementia. Additionally, the company has developed CimetrA, a nanoparticle-based treatment designed to modulate the immune system and address cytokine storms. Argent Biopharma emphasizes a data-driven approach to drug discovery, leveraging clinical research and standardized manufacturing to provide pharmaceutical-grade therapies to international markets.

Recent filings

Filing Released Lang Actions
Long Term Aquiol Licensing and Supply Agreement 3 pages 528.9KB
Regulatory Filings Classification · 90% confidence The document is an ASX-listed company announcement detailing a long-term licensing and supply agreement. It contains no financial statements or fundraising figures, nor is it an earnings release, management change, or dividend notice. It is not a formal report (10-K, IR) or a proxy/solicitation, nor is it an M&A takeover. It is a general regulatory announcement of a commercial deal, fitting the catch-all Regulatory Filings category (RNS).
2026-05-24 English
Appointment of Executive Director 3 pages 548.7KB
Board/Management Information Classification · 100% confidence The document is an announcement regarding changes in the company's board and senior management, specifically the appointment of an Executive Director and the transition of the Chairman to a Non-Executive role. It includes details about the leadership changes, strategic direction, and terms of employment for the new Executive Director and Chairman. There is no financial data, earnings information, or regulatory filings related to financial performance. The content clearly fits the category of Board/Management Information, as it focuses on management appointments and board transitions.
2026-05-05 English
Initial Director's Interest Notice - AC 1
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director's Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the appointment of a director and their relevant interests in securities, including shareholdings and contracts. This type of document is a report of personal share transactions or interests by company directors. It is not a financial report, earnings release, or management report. The document length is short and focused solely on director's interests, matching the definition of Director's Dealing filings.
2026-05-05 English
Final Director's Interest Notice - GH 1
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director's Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including the number and class of shares held, and the date the director ceased to be a director. This is a report of personal share transactions or holdings by a company director. The document length is short (2038 characters) and contains no financial statements or company performance data. Therefore, it fits the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades).
2026-05-05 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 703.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'March 2026 Quarterly Activity Report and Cash Flow' and includes detailed financial data such as cash flow statements, operating outflows, and financing activities for the quarter ended 31 March 2026. It references compliance with ASX Listing Rule 4.7C.3 and includes an Appendix 4C Quarterly Cash Flow report, which is a standard quarterly report for Australian listed entities. The document contains substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. It is not merely an announcement or a certification, but a comprehensive quarterly financial report with operational updates and cash flow statements. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2026-04-28 English
Completion of CannPal Asset Acquisition and Neuvis Option 2 pages 495.1KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 13 April 2026 about the completion of an acquisition of an asset (CannPal animal epilepsy asset) and an option to acquire a drug delivery platform (Neuvis®) by Argent BioPharma Ltd. It includes details about the strategic value of the acquisition, the assets involved, and comments from the CEO. There are no financial statements, quarterly or annual results, or regulatory filings referenced. The document is a corporate announcement about a capital transaction (acquisition) and strategic update. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The content aligns with Capital/Financing Update (CAP) as it relates to company fundraising, financing activities, or capital structure changes through acquisition. The document length is over 5,000 characters and contains substantive information about the transaction, not just a brief notice or report publication announcement. Therefore, the best classification is CAP with high confidence.
2026-04-12 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.